TransCode Therapeutics Inc (RNAZ) News

Moon landing coming next week 🚀🚀🚀🚀

Everyone is looking for that rat bastard Fitzgerald, He fucked investors all his career, millions and millions funneled in his pockets, he milked the big fat cow and fucked investors up the ass all his career

Here is Fitzgerald the rat bastard and all his lab rats that screwed investors all their careers, burn in hell you rat bastards
https://www.transcodetherapeutics.com/leadership.html

Can’t wait to see insiders decisively buying RNAZ, especially now when the votes went their way, In video with proactive investors Mr, Fitzgerald mentions that he believes this technology can be applicated to up to 18 different solid tumors

You want to sabotage the cure to cancer and fuck investors up the ass all your career Fitzgerald rat bastard of the earth, Hell is where you belong you motherfucker, you screwed investors all your career and destroyed the only hope for terminally ill cancer patients

Keep on hiding in your rat hole with your shareholders meeting video you bastard rat scumbag, come to the office Habibi proactive investors want to bust your ass open for fucking investors up the ass all your career you mother fucker

Take out the news on clinical trials you rat bastard scumbag mother fucker you want to sabotage all investors Fitzgerald CEO you love fucking investors up the ass, now there a line up of investors that will bust your ass wide open you piece of shit mother fucker

Yo Fitzgerald rat bastard proactive investors are all looking for you scumbag rat going to make sure they reverse your head up you ass you piece of shit rat bastard of the earth, You love fucking investors all your career you rat bastard,

RNAZ $10.00 explosions coming

Loaded.32-.34 
Toggle Mobile MenuThe Nobel Prize in Physiology or Medicine 2024Share thisFacebookXLinkedInEmail this pagePress release  Navigate to:   Summary- Victor Ambros- Gary Ruvkun Prize announcement Press release Advanced information
2024-10-07The Nobel Assembly at Karolinska Institutethas today decided to awardthe 2024 Nobel Prize in Physiology or Medicinejointly toVictor Ambros and Gary Ruvkunfor the discovery of microRNA and its role in post-transcriptional gene regulationThis year’s Nobel Prize honors two scientists for their discovery of a fundamental principle governing how gene activity is regulated.The information stored within our chromosomes can be likened to an instruction manual for all cells in our body. Every cell contains the same chromosomes, so every cell contains exactly the same set of genes and exactly the same set of instructions. Yet, different cell types, such as muscle and nerve cells, have very distinct characteristics. How do these differences arise? The answer lies in gene regulation, which allows each cell to select only the relevant instructions. This ensures that only the correct set of genes is active in each cell type.Victor Ambros and Gary Ruvkun were interested in how different cell types develop. They discovered microRNA, a new class of tiny RNA molecules that play a crucial role in gene regulation. Their groundbreaking discovery revealed a completely new principle of gene regulation that turned out to be essential for multicellular organisms, including humans. It is now known that the human genome codes for over one thousand microRNAs. Their surprising discovery revealed an entirely new dimension to gene regulation. MicroRNAs are proving to be fundamentally important for how organisms develop and function.Essential regulationThis year’s Nobel Prize focuses on the discovery of a vital regulatory mechanism used in cells to control gene activity. Genetic information flows from DNA to messenger RNA (mRNA), via a process called transcription, and then on to the cellular machinery for protein production. There, mRNAs are translated so that proteins are made according to the genetic instructions stored in DNA. Since the mid-20th century, several of the most fundamental scientific discoveries have explained how these processes work.Our organs and tissues consist of many different cell types, all with identical genetic information stored in their DNA. However, these different cells express unique sets of proteins. How is this possible? The answer lies in the precise regulation of gene activity so that only the correct set of genes is active in each specific cell type. This enables, for example, muscle cells, intestinal cells, and different types of nerve cells to perform their specialized functions. In addition, gene activity must be continually fine-tuned to adapt cellular functions to changing conditions in our bodies and environment. If gene regulation goes awry, it can lead to serious diseases such as cancer, diabetes, or autoimmunity. Therefore, understanding the regulation of gene activity has been an important goal for many decades.The flow of genetic information from DNA to mRNA to proteins. The identical genetic information is stored in DNA of all cells in our bodies. This requires precise regulation of gene activity so that only the correct set of genes is active in each specific cell type. © The Nobel Committee for Physiology or Medicine. Ill. Mattias KarlénIn the 1960s, it was shown that specialized proteins, known as transcription factors, can bind to specific regions in DNA and control the flow of genetic information by determining which mRNAs are produced. Since then, thousands of transcription factors have been identified, and for a long time it was believed that the main principles of gene regulation had been solved. However, in 1993, this year’s Nobel laureates published unexpected findings describing a new level of gene regulation, which turned out to be highly significant and conserved throughout evolution.Research on a small worm leads to a big breakthroughIn the late 1980s, Victor Ambros and Gary Ruvkun were postdoctoral fellows in the laboratory of Robert Horvitz, who was awarded the Nobel Prize in 2002, alongside Sydney Brenner and John Sulston. In Horvitz’s laboratory, they studied a relatively unassuming 1 mm long roundworm, C. elegans. Despite its small size, C. elegans possesses many specialized cell types such as nerve and muscle cells also found in larger, more complex animals, making it a useful model for investigating how tissues develop and mature in multicellular organisms. Ambros and Ruvkun were interested in genes that control the timing of activation of different genetic programs, ensuring that various cell types develop at the right time. They studied two mutant strains of worms, lin-4 and lin-14, that displayed defects in the timing of activation of genetic programs during development. The laureates wanted to identify the mutated genes and understand their function. Ambros had previously shown that the lin-4 gene appeared to be a negative regulator of the lin-14 gene. However, how the lin-14 activity was blocked was unknown. Ambros and Ruvkun were intrigued by these mutants and their potential relationship and set out to resolve these mysteries.(A) C. elegans is a useful model organism for understanding how different cell types develop. (B) Ambros and Ruvkun studied the lin-4 and lin-14 mutants. Ambros had shown that lin-4 appeared to be a negative regulator of lin-14. (C)Ambros discovered that the lin-4 gene encoded a tiny RNA, microRNA, that did not code for a protein. Ruvkun cloned the lin-14 gene, and the two scientists realized that the lin-4 microRNA sequence matched a complementary sequence in the lin-14 mRNA. © The Nobel Committee for Physiology or Medicine. Ill. Mattias KarlénAfter his postdoctoral research, Victor Ambros analyzed the lin-4 mutant in his newly established laboratory at Harvard University. Methodical mapping allowed the cloning of the gene and led to an unexpected finding. The lin-4 gene produced an unusually short RNA molecule that lacked a code for protein production. These surprising results suggested that this small RNA from lin-4 was responsible for inhibiting lin-14. How might this work?Concurrently, Gary Ruvkun investigated the regulation of the lin-14 gene in his newly established laboratory at Massachusetts General Hospital and Harvard Medical School. Unlike how gene regulation was then known to function, Ruvkun showed that it is not the production of mRNA from lin-14 that is inhibited by lin-4. The regulation appeared to occur at a later stage in the process of gene expression, through the shutdown of protein production. Experiments also revealed a segment in lin-14 mRNA that was necessary for its inhibition by lin-4. The two laureates compared their findings, which resulted in a breakthrough discovery. The short lin-4 sequence matched complementary sequences in the critical segment of the lin-14 mRNA. Ambros and Ruvkun performed further experiments showing that the lin-4 microRNA turns off lin-14 by binding to the complementary sequences in its mRNA, blocking the production of lin-14 protein. A new principle of gene regulation, mediated by a previously unknown type of RNA, microRNA, had been discovered! The results were published in 1993 in two articles in the journal Cell.The published results were initially met with almost deafening silence from the scientific community. Although the results were interesting, the unusual mechanism of gene regulation was considered a peculiarity of C. elegans, likely irrelevant to humans and other more complex animals. That perception changed in 2000 when Ruvkun’s research group published their discovery of another microRNA, encoded by the let-7 gene. Unlike lin-4, the let-7 gene was highly conserved and present throughout the animal kingdom. The article sparked great interest, and over the following years, hundreds of different microRNAs were identified. Today, we know that there are more than a thousand genes for different microRNAs in humans, and that gene regulation by microRNA is universal among multicellular organisms.Ruvkun cloned let-7, a second gene encoding a microRNA. The gene is conserved in evolution, and it is now known that microRNA regulation is universal among multicellular organisms. © The Nobel Committee for Physiology or Medicine. Ill. Mattias KarlénIn addition to the mapping of new microRNAs, experiments by several research groups elucidated the mechanisms of how microRNAs are produced and delivered to complementary target sequences in regulated mRNAs. The binding of microRNA leads to inhibition of protein synthesis or to mRNA degradation. Intriguingly, a single microRNA can regulate the expression of many different genes, and conversely, a single gene can be regulated by multiple microRNAs, thereby coordinating and fine-tuning entire networks of genes.Cellular machinery for producing functional microRNAs is also employed to produce other small RNA molecules in both plants and animals, for example as a means of protecting plants against virus infections. Andrew Z. Fireand Craig C. Mello, awarded the Nobel Prize in 2006, described RNA interference, where specific mRNA-molecules are inactivated by adding double-stranded RNA to cells.Tiny RNAs with profound physiological importanceGene regulation by microRNA, first revealed by Ambros and Ruvkun, has been at work for hundreds of millions of years. This mechanism has enabled the evolution of increasingly complex organisms. We know from genetic research that cells and tissues do not develop normally without microRNAs. Abnormal regulation by microRNA can contribute to cancer, and mutations in genes coding for microRNAs have been found in humans, causing conditions such as congenital hearing loss, eye and skeletal disorders. Mutations in one of the proteins required for microRNA production result in the DICER1 syndrome, a rare but severe syndrome linked to cancer in various organs and tissues.Ambros and Ruvkun’s seminal discovery in the small worm C. elegans was unexpected, and revealed a new dimension to gene regulation, essential for all complex life forms.

It will happen sooner than later brother, load and hold for glory

Yes this one has potential hedgies beat it down for a reason. One sliver of positive news and a 300% gain is easy and even more down the line. Load them while they are cheap.

Come to the office Habibi Fitzgerald so proactive investors can reverse your head up your ass you rat bastard scumbag of the earth

Vote yes for a banana up Fitzgerald ass the dirty scumbag rat piece of shit of the earth, come to the offices Habibi for a nice surprise for you

Vote no, watch it short squeeze out of the universe brothers

Houston All aboard the texas spaceship

Texas cowboys territory brothers,

🚀🚀🚀SHORT SQUEEZE MOTHER OF ALL CANCER BREAKTHROUGHS 🚀🚀🚀🚀

Load and hold for A/H news brothers The texas rattle snake will strike

The world has been waiting for to long, the time has come brothers

It’s time to shine on the world stage texas rattle snake
https://www.cancer.gov/research/infrastructure/cancer-centers/find/mdanderson

🔥🔥Light up the cure to cancer🔥🔥All aboard brothers

Big bang theory brothers

Once the clock strikes .40 gap up to the sky brothers

Next leg up $weet$$ let$$ do it right$$$

Bust that move… The world is watching..

Whales are all on the lookout for cancer destroying TTX

One big $lap to the dollar city $weet$$$

It’$ the moment of truth $weet$$$ ri$k foe reward$$$$$

Drop your pant$$ fill em bid$$$ $weet$$ party is getting $tarted$$$

Texas rattle snake will strike…

buyout rumor leaked brothers it’s coming…

.39-.40 up next then .46-.47 if it takes a few weeks chance to load more .30s

Yes ...forming a nice bullish candle...🥳

RNAZ .37 looking better for bottom feeder fishing 

And insiders seem to stay away from RNAZ stock as from plague. I did not receive a single response to my 3 emails I sent to Tom and/or IR. Not even acknowledging them or any of my concerns. That is how much a shareholder means to the management. Just to take our money and to vote Yes to approve them using us the same toxic ways. The change is overdue.

There are over 100 studies of the role of miR-10b in at least 18 cancer types over the last 15 years, including some with contributions from our co-founders, making it one of the most studied microRNAs. Studies have shown that an inhibition of miR-10b "prevents the onset of metastasis and eliminate existing metastases, even after treatment has been discontinued." Metastases are responsible for about 90% of all cancer deaths, due to a lack of therapeutics. In Phase 0, a microdose of TTX-MC138 reduced miR-10b by 66%, 24 hours after injection. In another study, MN-anti-miR10b decreased miR-10b by 90% in 24-48 hours, and a 99% downregulation was observed within two weeks. It seems as though this data is quick to ascertain. It's been over two months since the first Phase 1 patients were dosed with 0.4mg/kg of TTX-MC138.

How can the CEO say there can be no assurance that this data will be released?

Come to the office Habibi, Fitzgerald it's been so long you've been hiding like a dirty rat scumbag bastard of the the earth you piece of shit

Going to make sure an R/S up Fitzgerald ass rat bastard scumbag piece of shit of the earth,

You never know is right but always good to when an R/S is on the table...🥳

Monster news can hit the wires A/H or tomorrow morning brothers be on the lookout …

Texas cowboys can pull the trigger at any moment brother

You never know when the texas rattle shake will strike timing is key

Did a search on XCUR and your RNAZ post came up...🥳...Don't know if you are aware...

BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Board and Management of TransCode Therapeutics (NASDAQ: RNAZ) today issued the following open letter to shareholders of the Company:

Dear Shareholders,

At our upcoming Special Meeting to be held November 22, shareholders are being asked to authorize our Board of Directors to effect a reverse split — only if the Board determines that doing so is necessary as described below.

Many shareholders rightly ask why this request. Some believe that the potential announcement of additional positive clinical data or other good news will favorably impact our stock price. However, there is no assurance that any good news will occur, will occur by the deadline required, or that the stock will rise after any such positive announcement(s).

A reverse split is NOT something directors or management wishes to do — we all hope it won’t be needed. But the Nasdaq Hearings Panel that approved the extension to continue our Nasdaq listing did so on the condition that our shareholders authorize a reverse split — should one be necessary. The reverse split will not be necessary if our stock closes at $1.00 per share or more for any ten-day period prior to December 31, 2024.

If our stock does not meet this Nasdaq requirement, and we do not have your vote in favor of the reverse split, Nasdaq will delist our stock. A Nasdaq delisting would in all likelihood have a material adverse effect on the value of our company and the value of your stock.

Our assessment boils down to this: your vote is your decision about whether you support our efforts to maintain our Nasdaq listing. Given our need to raise additional capital as soon as possible to continue the clinical trial and other operations, we believe having our stock remain on Nasdaq is critical to raising the needed capital.

TransCode’s management and directors are unanimously determined to maintain our Nasdaq listing. This is why we need you to authorize the reverse split, with all of us hoping that we will not have to implement this decision.

We call for your understanding and greatly appreciate your support.

The texas rattle snake can strike anytime now… keep your eyes open

Unless the texas rattle snake strikes fda fast track status for the terminally ill cancer patients

Technicals oversold look at XCUR today lol. Most penny bios are just daytrades then load them beat down for the biggest gains. Adding .32-.34 until technicals change. Still a chance it goes to .20s again. Anything possible 

All holding, The well is dry

Fill em bid$$ $weet$$ I got your back$$$$

Partnership, merger, buyout, junkie$$$$ it’s coming in your face $weet$$$